Enhancing Neural Transmission in Multiple Sclerosis (4-Aminopyridine Therapy)

The Safety Profile of Dalfampridine Extended Release in Multiple Sclerosis Clinical Trials

(2012) David R. Cornblath et al.   CLINICAL THERAPEUTICS

Dalfampridine in multiple sclerosis: From symptomatic treatment to immunomodulation

(2011) Carmen Espejo et al.   CLINICAL IMMUNOLOGY

Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis

(2011) Craig I. Coleman et al.   CURRENT MEDICAL RESEARCH AND OPINION

Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis

(2010) Howard L. Zwibel   ADVANCES IN THERAPY

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis

(2010) Andrew D. Goodman et al.   ANNALS OF NEUROLOGY

Contribution of impaired mobility to patient burden in multiple sclerosis

(2009) Matthew H. Sutliff   CURRENT MEDICAL RESEARCH AND OPINION

Aminopyridines Potentiate Synaptic and Neuromuscular Transmission by Targeting the Voltage-activated Calcium Channel β Subunit

(2009) Zi-Zhen Wu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Single-Dose Pharmacokinetics of Sustained-Release Fampridine (Fampridine-SR) in Healthy Volunteers and Adults With Renal Impairment

(2009) William Smith et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial

(2009) Andrew D Goodman et al.   LANCET

Sustained-Release Fampridine for Symptomatic Treatment of Multiple Sclerosis

(2008) Anne R Korenke et al.   ANNALS OF PHARMACOTHERAPY

Dose comparison trial of sustained-release fampridine in multiple sclerosis

(2008) A. D. Goodman et al.   NEUROLOGY

Seizures in Multiple Sclerosis

(2002) Dragoslav V. Sokić et al.   EPILEPSIA